US RE50,202 E1
Nasal respiratory assembly and methods of use
Sandra Alphonse, La Mesa, CA (US)
Assigned to Sandra Alphonse, La Mesa, CA (US)
Filed by Sandra Alphonse, La Mesa, CA (US)
Filed on Sep. 30, 2021, as Appl. No. 17/491,513.
Application 17/491,513 is a continuation of application No. PCT/US2012/072153, filed on Dec. 28, 2012.
Application 17/491,513 is a reissue of application No. 14/739,898, filed on Jun. 15, 2015, granted, now 10,426,909, issued on Oct. 1, 2019.
Int. Cl. A61M 16/06 (2006.01); A61M 16/08 (2006.01); A61M 16/10 (2006.01); A61M 16/12 (2006.01); A61M 16/16 (2006.01)
CPC A61M 16/06 (2013.01) [A61M 16/0683 (2013.01); A61M 16/0875 (2013.01); A61M 16/1045 (2013.01); A61M 16/12 (2013.01); A61M 16/16 (2013.01)] 13 Claims
OG exemplary drawing
 
[ 14. A nasal respiratory assembly for delivering a therapeutic treatment to a patient having nasal cavities, the nasal respiratory assembly comprising:
a) a mask comprising a top surface and a base, wherein an exhaust port is positioned on or proximate to said top surface;
b) at least one intake port coupled with the mask along said top surface, wherein the at least one intake port comprises an internal vent having a gas directing element comprising one or more planar surfaces or louvers within the at least one intake port, and wherein the gas directing element is configured to direct pressurized gas away from entering said patient's nasal cavities directly;
c) a hose configured to be received by the at least one intake port; and
d) at least one medication delivery port positioned upstream of the at least one intake port and configured to supply medication to the mask;
wherein the nasal respiratory assembly is configured to deliver said therapeutic treatment without providing a flow of pressurized gas directly into the patient's nasal cavities.]